Core Viewpoint - The report presented at the AASLD annual meeting is a significant showcase of the company's progress in innovative drug development for hepatitis B treatment, aimed at gaining international attention in the field of hepatology and fostering friendly international exchanges and discussions [1] Group 1 - The company is committed to steadily advancing the clinical research and development of innovative hepatitis B drugs [1] - The company will fulfill its obligation to disclose information regarding the progress of innovative drugs in a timely manner, in accordance with regulations [1]

Core Viewpoint - The company Guangshentang (300436) stated that the U.S. tariff policy on pharmaceuticals has not materially affected the research and development progress of its drug GST-HG141, and that its production and operations are normal [1] Group 1 - The company management remains focused on its core business and is steadily advancing the research and development of innovative hepatitis B drugs [1]